Last reviewed · How we verify
Etoricoxib + Cyanocobalamin fixed dose
Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while cyanocobalamin (vitamin B12) supports neurological function and red blood cell formation.
Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while cyanocobalamin (vitamin B12) supports neurological function and red blood cell formation. Used for Inflammatory pain conditions (likely osteoarthritis, rheumatoid arthritis, or musculoskeletal pain with concurrent B12 deficiency).
At a glance
| Generic name | Etoricoxib + Cyanocobalamin fixed dose |
|---|---|
| Also known as | Etori + Cyano |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | COX-2 selective inhibitor + vitamin B12 supplement |
| Target | COX-2 enzyme; cyanocobalamin (B12 cofactor) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces prostaglandin synthesis, thereby decreasing inflammation and pain. Cyanocobalamin is an essential B vitamin required for neurological function, DNA synthesis, and erythrocyte maturation. This fixed-dose combination likely targets pain conditions where B12 deficiency or neurological involvement may be present.
Approved indications
- Inflammatory pain conditions (likely osteoarthritis, rheumatoid arthritis, or musculoskeletal pain with concurrent B12 deficiency)
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Headache
- Dizziness
- Hypertension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: